SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is under pressure after a weaker-than-expected quarterly report and a sharply reduced outlook, with traders focused on heavy spending to expand its Predictions business and the impact on profitability. Many see competition from Kalshi and Polymarket and question managements spending, while some argue the core sportsbook is still growing and the selloff is overdone.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Traders are focused on the approaching FDA decision on Capricors deramiocel application for Duchenne muscular dystrophy, citing HOPE-3 upper-limb data and a support letter from 28 physician-scientists. Many expect approval and point to short interest and call activity as potential fuel for a squeeze, while others stress that a rejection or complete response letter remains possible and the outcome is uncertain.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys three-year engine-supply, licensing, and engineering agreement with AST SpaceMobile for its planned heavy-lift rocket is driving attention. Traders largely view the deal as a major boost to Fireflys backlog and funding outlook, while some remain cautious about execution, undisclosed payment details, and whether the stock can sustain its sharp move.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins strong quarterly results, higher outlook, and expanded share-repurchase authorization have driven a sharp rally, with traders highlighting its AI-powered advertising model and cash generation. Bulls see the results as evidence of renewed growth, while skeptics warn that the surge may be overextended and question whether ad growth can persist.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axons quarterly results missed expectations and the company lowered its full-year outlook, citing federal procurement delays, driving a sharp selloff. Traders are split between viewing the drop as an overreaction and buying opportunity and warning that valuation and weak price action could leave further downside.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas stronger-than-expected quarterly results, surprise profit and raised revenue outlook are driving a sharp, volatile rally. Traders are split on whether vaccine sales mark a durable recovery or whether the gains are overextended given cash burn and valuation; early cancer-pipeline data adds to the bullish case but remains preliminary.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure amid weak crypto trading activity, Bitcoins slide, and contagion concerns after the Binance hack, with a Morgan Stanley downgrade adding to the bearish mood. Many traders cite fresh lows and fear more downside, while some see the selloff as overdone or expect customers to shift from Binance to Coinbase.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is drawing attention as part of a sharp selloff in memory and semiconductor stocks, with traders pointing to worries that political uncertainty and resistance to data-center expansion could weigh on AI infrastructure spending. Some see the decline as sector-wide panic and a buying opportunity given WDCs business prospects, while others fear the AI-storage cycle may cool; traders also note no clear company-specific news behind the drop.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Schwab and thinkorswim platform disruptions are dominating discussion, with users reporting login failures, delayed or unavailable order functions, and inaccurate account or market data. Traders are frustrated and some say they may move to other brokers; Schwabs notice says execution is unaffected by the reporting delay and cautions against resubmitting orders because that could create duplicates.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A Q3 earnings beat and upbeat outlook have fueled discussion, but traders are debating the stocks muted reaction: bulls point to growth in data-center leases and Googles credit support for financing tied to the Anthropic lease, while skeptics focus on debt, buildout execution and sector headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School

Vyome Holdings, Inc. (Nasdaq: HIND) ("Vyome"), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today congratulated its Scientific Co-Founder and Director, Dr. Shiladitya Sengupta, PhD, on his promotion to Professor of Medicine at Harvard...

Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market

Vyome Holdings, Inc. (Nasdaq: HIND) (Vyome), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/787,303...

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

Vyome Holdings, Inc. (Nasdaq: HIND) (Vyome or the Company), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, today announced the appointment of senior financial executive Jerry Leonard, CPA, MBA, as Chief...

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

Vyome Holdings, Inc. (Nasdaq: HIND, Vyome), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corporate update. Krishna Gupta, Chairman, Vyome Holdings...

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Vyome Holdings, Inc. (NASDAQ: HIND) (Vyome or the Company), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, announces that the China National Intellectual Property Administration (CNIPA) has granted a...

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

Vyome Holdings, Inc. (Nasdaq: HIND)(Vyome), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides a corporate update. Krishna Gupta, Chairman of Vyome, said...

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (Impetis), a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. Janus kinase (JAK...

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malignant Fungating Wounds (MFW) at the 2026 American Association for Cancer...

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety...

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Vyome Holdings, Inc., (Vyome) (Nasdaq: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its financial results and corporate and clinical milestones following its successful listing on Nasdaq. This quarter marks Vyomes first annual...

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. It focuses on therapeutic solutions that target formulations for site-targeted applications. The company was founded on January 2, 2008 and is headquartered in Cambridge, MA.

Vyome Holdings Inc.

HIND Stock Rallies 70% Pre-Market Today – Find Out Why

Equity

Bullish Sentiment

Vyome Holdings, Inc. (HIND) announced on Wednesday that its VT-1908 eyedrops has been shown to significantly reduce uveitis scores in preclinical models. Shares of the company rallied 18% on Wednesday morning at the time of writing.&nbsp;Uveitis is the inflammation of a part of the eye and is implicated in approximately 30,000 new cases of legal blindness annually in the United States alone, according to Vyome. &nbsp;In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, and the efficacy of the drug was found to be similar to a clinically used steroid, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250917093826/en/Vyome-Presents-Strong-Data-Showing-Topical-VT-1908-is-an-Effective-Treatment-for-Uveitis-Opening-Up-a-%243B-Addressable-Market-Opportunity">stated</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HIND">HIND stock</a> jumped from ‘neutral’ to ‘extremely bullish territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels. Shares of the company traded as high as 70% in the pre-market session.&nbsp;According to Vyome, steroids are the first line of treatment for uveitis, but many patients do not respond to them, and they also cause major complications. “There is a huge unmet need for a topically administered drug to replace steroid use in the eye. Vyome is developing VT-1908 to address this major unmet need,” the company said while adding that the broader addressable global market to treat inflammation in the eye is expected to exceed $20 billion by 2030.“We are excited with the preclinical efficacy signals. We expect to initiate Phase 1/2 clinical trial in the second half of 2026,” CEO Venkat Nelabhotla said. While the company will initially target uveitis, the long-term goal is to replace steroids to treat ocular inflammation, he said.HIND stock is down by 98% this year and by about 99% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-its-obesity-pill-topped-novo-nordisks-oral-drug-in-late-stage-diabetes-trial/chDGpSDRd6X">Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, Vyome said. 

Fundamental investor

Technical trader

A mix of both

Fundamental analysis looks at earnings, valuation, and business quality, while technical analysis focuses on chart patterns, price action, and indicators, and many investors blend the two. How do you decide what to buy: fundamentals or technicals? Vote and explain your reasoning in the comments.

Feed

News

Sentiment

Earnings

Fundamentals

Info

HIND Vyome Holdings Inc.

Fundamentals

Latest HIND News